Browse by:

Biostage tries to fast track throat regrowth implants

Sam Bonacci |

Holliston biotechnology firm Biostage has filed for a designation that would allow it to fast-track registrations for its Cellspan esophageal implants and gain a full exemption from the FDA's...

Framingham company acquired, 13 employees retained

Sam Bonacci |

Framingham's Active Broadband Networks has been acquired for its technology by Louisiana-based CenturyLink that will absorb 13 of the company's employees as part of its testing team.

Brexit impacting Massachusetts budget, businesses


Great Britain's vote to break free from the European Union sent ripples through the world's financial markets Friday, adding to the global concerns being watched by those with a stake in the...

Medtronic to buy Heartware for $1.1B

Sam Bonacci |

Medtronic announced Monday that it will buy Framingham's Heartware International for $1.1 billion as the Dublin-based company seeks to expand its heart failure portfolio.

Imugen sold for $22M to Marlborough biotech

Sam Bonacci |

Imugen will be sold to fellow Marlborough biotech company Oxford Immunotec for $22.2 million, with the deal expected to close next week.

WBJ announces new manufacturing, healthcare reporters

Worcester Business Journal's Staff Writer Laura Finaldi has taken over as the publication's healthcare reporter while new hire John McIntyre will serve as the organization's manufacturing reporter.

Staples partners with Katy Perry to support teachers

Sam Bonacci |

Framingham’s Staples has donated $1 million and partnered with singer Katy Perry to encourage continued support of teachers.

GE opens $27M, 500-job facility in Marlborough

Sam Bonacci |

GE Healthcare Life Sciences held the grand opening for its U.S. headquarters in Marlborough on Thursday, highlighting the division's $27 million investment in the new facility.

Waters partners with Singapore to find cancer markers

Laura Finaldi |

Milford-based Waters Corp. on Monday announced a collaboration with the Bioprocessing Technology Institute in Singapore's Agency for Science, Technology and Research.

Biostage closer to human testing on momentum of $5M stock offering

Sam Bonacci |

Biostage is moving closer to human trials of its esophagus regeneration technology, anticipated to take place in 2017, on the back of an additional $5 million in funding gained through a stock offer.

Copyright 2016 New England Business Media